Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Background The phase III EMILIA and TH3RESA trials demonstrated clinical benefits of trastuzumab emtansine (T-DM1) therapy in patients with previously treated HER2-positive metastatic breast cancer (MBC). Data from these and other trials showed that T-DM1–associated survival benefits were observed a...

Full description

Saved in:

Bibliographic Details
Published in:	BMC cancer Vol. 19; no. 1; pp. 517 - 14
Main Authors:	Perez, Edith A., de Haas, Sanne Lysbet, Eiermann, Wolfgang, Barrios, Carlos H., Toi, Masakazu, Im, Young-Hyuck, Conte, Pier Franco, Martin, Miguel, Pienkowski, Tadeusz, Pivot, Xavier B., Burris, Howard A., Stanzel, Sven, Patre, Monika, Ellis, Paul Anthony
Format:	Journal Article
Language:	English
Published:	London BioMed Central 30.05.2019 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Analysis Antineoplastic agents Biological markers Biomarker Biomarkers Biomedical and Life Sciences Biomedicine Breast cancer Cancer metastasis Cancer Research Clinical trials Comparative analysis Dosage and administration Drug therapy Epidermal growth factor ErbB-2 protein Experimental therapeutics and drug development Gene amplification Gene expression Health Promotion and Disease Prevention HER2 Immunotherapy Kinases MARIANNE Medical prognosis Medicine/Public Health Messenger RNA Metastases Metastasis Metastatic breast cancer Monoclonal antibodies mRNA Multivariate analysis Mutation Oncology Patients Pertuzumab PIK3CA Protein expression Proteins PTEN protein Research Article Retirement benefits RNA Studies Surgical Oncology Targeted cancer therapy Trastuzumab Tumors Biomarker Trastuzumab emtansine PTEN Metastatic breast cancer mRNA T-DM1 HER2 Progression-free survival MARIANNE PIK3CA
ISSN:	1471-2407, 1471-2407
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!